Citations

Clear

410 citation(s) found for "Shu, Yu".

P1‐165: Generation and characterization of FTLD‐U and ALS cell model with inducible expression of TDP‐43 C‐terminal fragment
Xu, Yafei , Ko, Li‐wen, Yen, Shu‐Hui, Petrucelli, Leonard , Zhang, Yongjie , Gendron, Tania F.

Mayo Clinic

Alzheimer's & Dementia | July 11, 2010 | Volume: 6 | Issue: 4S_Part_7 | Pages: No page available

10.1016/j.jalz.2010.05.715 Get It

Case report: Idiopathic acquired diffuse osteosclerosis in a young woman
BEYER, H. STEPHEN, Parfitt, A. M., Shih, Mei Shu, Anderson, Quentin, Heath, Hunter

Mayo Clinic

Journal of Bone and Mineral Research | February 3, 2010 | Volume: 5 | Issue: 12 | Pages: 1257-1263

10.1002/jbmr.5650051211 | PMID 2075839 Get It

Abstract We describe a young woman who acquired a painful, diffuse osteosclerosis of the cervical, thoracic, and lumbar spine, pelvis, and long bones of the legs as an adult. Bone densitometry showed a large increase in apparent bone density. Skeletal radiographs demonstrated progressive endosteal and periosteal thickening of the cortices. A bone scan showed increased uptake of radiolabel. The serum total alkaline phosphatase and 1,25-(OH)2D3 levels were substantially elevated and the immunoreactive PTH was mildly elevated. Bone biopsy showed increased bone turnover, especially on endocortical and intracortical surfaces, but the structural indices were normal. By 4 years after presentation the bone pain had remitted and the serum alkaline phosphatase, 1,25-(OH)2D3, and PTH were normal. No cause for the occurrence of osteosclerosis in this patient could be found.
Differential Responses to Smith D Autoantigen by Mice with HLA-DR and HLA-DQ Transgenes: Dominant Responses by HLA-DR3 Transgenic Mice with Diversification of Autoantibodies to Small Nuclear Ribonucleoprotein, Double-Stranded DNA, and
Jiang, Chao , Deshmukh, Umesh S. , Gaskin, Felicia, Bagavant, Harini , Hanson, Julie A., David, Chella S., Fu, Shu Man

Mayo Clinic

The Journal of Immunology | December 10, 2009 | Volume: 184 | Issue: 2 | Pages: 1085-1091

10.4049/jimmunol.0902670 | PMID 20007529 Get It

Abstract Anti-Smith (Sm) D autoantibodies are specific for systemic lupus erythematosus. In this investigation, the influence of HLA-D genes on immune responses to SmD was investigated. Mice with HLA-DR3, HLA-DR4, HLA-DQ0601, HLA-DQ0604, or HLA-DQ8 transgenes were immunized with recombinant SmD1, and their Ab responses were analyzed. Analysis by ELISA showed that all strains responded well to SmD. However, when synthetic SmD peptides were used as substrate, DR3 mice had the highest Ab response followed by DQ8, DQ0604, DQ0601, and DR4. A similar trend was observed in Western blot analysis using WEHI 7.1 cell lysate as the substrate, with the exception that DR4 mice did not generate detectable amounts of Abs. Only sera from DR3 and DQ0604 mice immunoprecipitated A-ribonucleoprotein (RNP), SmB, and SmD. Intermolecular epitope spreading to A-RNP and SmB was evident in DR3 and DQ0604 mice, as sera depleted of anti-SmD Abs were reactive with these proteins. DR3 mice also generated an immune response to C-RNP. Anti-nuclear Abs were detected in the majority of the DR3 mice, whereas moderate reactivities were seen in DQ0604 and DQ8 mice. Interestingly, only DR3 mice mounted an anti-dsDNA Ab response. Approximately half of the anti-dsDNA Abs were cross-reactive with SmD. Ab responses correlated with the strength of the T cell responses. Thus, HLA-DR3 appears to be the dominant HLA-D gene that determines the magnitude and quality of the anti-SmD immune response. In addition, our findings provide insights into the origin of the anti-dsDNA Abs often detected in patients with systemic lupus erythematosus.
Fine Mapping of Chromosome 6q23-25 Region in Familial Lung Cancer Families Reveals RGS17 as a Likely Candidate Gene
You, Ming , Wang, Daolong, Liu, Pengyuan , Vikis, Haris G., James, Michael A. , Wang, Yian , Jia, Dongmei , Wen, Weidong, Sun, Zhifu , Pinney, Susan M. , Zheng, Wei , Shu, Xiao‐Ou , Long, Jirong , Gao, Yu-Tang, Xiang, Yong-Bing , Chow, Wong‐Ho , Rothman, Nat, Petersen, Gloria M. , Cunningham, Julie M. , Wiest, Jonathan S., Fain, Pamela R., Schwartz, Ann G. , Girard, Luc , Gazdar, Adi, Gaba, Colette , Rothschild, Henry, Mandal, Diptasri , Coons, Teresa, Lee, Juwon , Kupert, Elena, Seminara, Daniela, Bailey‐Wilson, Joan E. , Anderson, Marshall W., Lü, Yan , Wang, Min , Chen, Qiong , Liu, Yan , Yang, Ping , Andrade, Mariza de , Wu, Yanhong , Minna, John Dorrance , Amos, Christopher I. , Sun, Zhifu , Wilson, Richard K , Shu, Xiao-Ou , Zheng, Wei , Pinney, Susan M

Mayo Clinic

Clinical Cancer Research | April 7, 2009 | Volume: 15 | Issue: 8 | Pages: 2666-2674

10.1158/1078-0432.ccr-08-2335 | PMID 19351763 Get It

Abstract Purpose: We have previously mapped a major susceptibility locus influencing familial lung cancer risk to chromosome 6q23-25. However, the causal gene at this locus remains undetermined. In this study, we further refined this locus to identify a single candidate gene, by fine mapping using microsatellite markers and association studies using high-density single nucleotide polymorphisms (SNP). Experimental Design: Six multigenerational families with five or more affected members were chosen for fine-mapping the 6q linkage region using microsatellite markers. For association mapping, we genotyped 24 6q-linked cases and 72 unrelated noncancer controls from the Genetic Epidemiology of Lung Cancer Consortium resources using the Affymetrix 500K chipset. Significant associations were validated in two independent familial lung cancer populations: 226 familial lung cases and 313 controls from the Genetic Epidemiology of Lung Cancer Consortium, and 154 familial cases and 325 controls from Mayo Clinic. Each familial case was chosen from one high-risk lung cancer family that has three or more affected members. Results: A region-wide scan across 6q23-25 found significant association between lung cancer susceptibility and three single nucleotide polymorphisms in the first intron of the RGS17 gene. This association was further confirmed in two independent familial lung cancer populations. By quantitative real-time PCR analysis of matched tumor and normal human tissues, we found that RGS17 transcript accumulation is highly and consistently increased in sporadic lung cancers. Human lung tumor cell proliferation and tumorigenesis in nude mice are inhibited upon knockdown of RGS17 levels. Conclusion: RGS17 is a major candidate for the familial lung cancer susceptibility locus on chromosome 6q23-25.
Trends in the Association Between Age and In-Hospital Mortality After Percutaneous Coronary Intervention
Peterson, Eric D., Roe, Matthew T. , Spertus, John A. , Rumsfeld, John S., Anderson, H. Vernon, Klein, Lloyd W. , Holmes, David R. , Singh, Mandeep , Ou, Fang‐Shu , Ho, Kalon K.L. , Spertus, John A

Mayo Clinic

Circulation: Cardiovascular Interventions | February 11, 2009 | Volume: 2 | Issue: 1 | Pages: 20-26

10.1161/circinterventions.108.826172 | PMID 20031689 Get It

Background— Temporal trends and contemporary data characterizing the impact of patient age on in-hospital outcomes of percutaneous coronary interventions are lacking. We sought to determine the importance of age by assessing the in-hospital mortality of stratified age groups in the National Cardiovascular Data Registry. Methods and Results— In-hospital mortality after percutaneous coronary intervention on 1 410 069 patients was age stratified into 4 groups—group 1 (age <40, n=25 679), group 2 (40 to 59, n=496 204), group 3 (60 to 79, n=732 574), and group 4 (≥80, n=155 612)—admitted from January 1, 2001, to December 31, 2006. Overall in-hospital mortality was 1.22%; in-hospital mortality was 0.60%, 0.59%, 1.26%, and 3.16% in groups 1 to 4, respectively, P <0.0001. Overall temporal improvement per calendar year in the adjusted in-hospital mortality after percutaneous coronary intervention was noted in most groups; however, this finding was significant only in the 2 older age groups, group 3 (odds ratio, 0.94; 95% CI, 0.92 to 0.96) and group 4 (odds ratio, 0.95; 95% CI, 0.92 to 0.97). The absolute mortality reduction was greatest in the most elderly group, those over the age of 80 years. Conclusions— In-hospital mortality after percutaneous coronary intervention has fallen for all age groups over the past 6 years. However, the largest absolute reduction was seen among patients 80 years of age or older.
Cathepsin D Is the Main Lysosomal Enzyme Involved in the Degradation of α-Synuclein and Generation of Its Carboxy-Terminally Truncated Species
Sevlever, Daniel , Jiang, Peizhou , Yen, Shu-Hui

Mayo Clinic

Biochemistry | August 15, 2008 | Volume: 47 | Issue: 36 | Pages: 9678-9687

10.1021/bi800699v | PMID 18702517 Get It

Using leucine zipper to facilitate α‐synuclein assembly
Jiang, Peizhou , Ko, Li‐wen, Jansen, Karen, Golde, Todd E. , Yen, Shu‐Hui

Mayo Clinic

The FASEB Journal | May 20, 2008 | Volume: 22 | Issue: 9 | Pages: 3165-3174

10.1096/fj.08-108365 | PMID 18492724 Get It

ABSTRACT The accumulation of filamentous a‐synuclein (α‐S) is associated with Parkinson's disease. It remains controversial as to the mode (antiparallel or parallel) of α‐S self‐assembly and whether an exact alignment of the central hydrophobic region is essential. In the present study, we performed in vitro assembly using α‐S with or without the attachment of artificial leucine zippers (Zips) capable of forming either parallel or antiparallel coiled coils and included a spacer in one derivative. Results showed that Zips accelerate filament assembly in both the parallel and antiparallel fashions, that a precise alignment of the central hydrophobic region is not essential, and that the antiparallel pairs displayed the highest thioflavin T signals. More importantly, cells expressing Zip‐fused α‐S, but not α‐S alone, formed α‐S immunopositive and thioflavin S‐positive inclusions in 7 days. The results suggest that α‐S can assemble in both parallel and antiparallel modes but have a higher tendency to assemble in the latter mode and that cells overexpressing Zip‐fused α‐S may be used to screen α‐S assembly inhibitors due to enhanced ability to form inclusions.—Jiang, P., Ko, L., Jansen, K. R., Golde, T. E., Yen, S.‐H. Using leucine zipper to facilitate α‐synuclein assembly. FASEB J. 22, 3165–3174 (2008)
The Bcl-2 Family Protein Inhibitor, ABT-737, Has Substantial Antimyeloma Activity and Shows Synergistic Effect with Dexamethasone and Melphalan
Trudel, Suzanne , Stewart, A. Keith , Li, Zhihua , Shu, Yanjun, Liang, Sheng-Ben, Trieu, Young, Reece, Donna , Paterson, Josh, Wang, Dingyan , Wen, Xiao‐Yan , Liang, Sheng‐Ben , Wen, Xiao-Yan

Mayo Clinic

Clinical Cancer Research | January 25, 2007 | Volume: 13 | Issue: 2 | Pages: 621-629

10.1158/1078-0432.ccr-06-1526 | PMID 17255285 Get It

Abstract Purpose: The aim of this study is to investigate the antimyeloma activity of a novel Bcl-2 family inhibitor, ABT-737, in preclinical treatment of multiple myeloma. Experimental Design: The antimyeloma activity of ABT-737 was evaluated in cultured myeloma cell lines and patient myeloma samples, and in a xenograft mouse myeloma model. Drug combination therapy using ABT-737 with other commonly used myeloma drugs was also investigated. Results: MY5 and JJN3 cell lines exhibited the most sensitivity to ABT-737 with an EC50 of 0.2 and 0.5 μmol/L, respectively, with increased cell apoptosis and elevated activated caspase-3. We identified two distinct groups of myeloma patient samples that were either sensitive or resistant to the drug. Four of 15 patient bone marrow samples (27%) were highly sensitive to ABT-737 at doses of 0.25 and 0.5 μmol/L, which eliminated 80% to 90% of myeloma cells as a result of cellular apoptosis 3 days after drug treatment. ABT-737 showed a synergistic effect when combined with dexamethasone or melphalan in inducing myeloma cell death. Furthermore, the dexamethasone-resistant MM1(Dex)R myeloma cell line was highly sensitive to 0.2 μmol/L ABT-737. As determined by colony assay, little or no detectable toxicity to patient hematologic progenitor cells was observed at 1 μmol/L ABT-737. ABT-737 dose dependently suppressed tumor growth in a xenograft MY5 mouse model. Conclusions: These studies show substantial antimyeloma activity of ABT-737 as a single agent or in combination with dexamethasone or melphalan and suggest a rationale for future clinical trials.
P2–049: Effect of proteasomal inhibitors on tau truncation and aggregation in a cellular model of tauopathy
Ko, Li‐wen, Fields, Tania Gendron, Yen, Shu‐Hui, Hamano, Tadanori

Mayo Clinic

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_8 | Pages: No page available

10.1016/j.jalz.2006.05.886 Get It

Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP
Lewis, Jada , Dickson, Dennis W. , Lin, Wen-Lang, Chisholm, Louise, Corral, Anthony, Yen, Shu‐Hui, Skipper, Lisa , Yager, Debra, Eckman, Chris, Hardy, John , Hutton, Mike, Jones, Graham L. , Sahara, Naruhiko , McGowan, Eileen , Dickson, Dennis W , Hardy, John

Mayo Clinic

Science | July 27, 2002 | Volume: 293 | Issue: 5534 | Pages: 1487-1491

10.1126/science.1058189 | PMID 11520987 Get It

JNPL3 transgenic mice expressing a mutant tau protein, which develop neurofibrillary tangles and progressive motor disturbance, were crossed with Tg2576 transgenic mice expressing mutant β-amyloid precursor protein (APP), thus modulating the APP-Aβ (β-amyloid peptide) environment. The resulting double mutant (tau/APP) progeny and the Tg2576 parental strain developed Aβ deposits at the same age; however, relative to JNPL3 mice, the double mutants exhibited neurofibrillary tangle pathology that was substantially enhanced in the limbic system and olfactory cortex. These results indicate that either APP or Aβ influences the formation of neurofibrillary tangles. The interaction between Aβ and tau pathologies in these mice supports the hypothesis that a similar interaction occurs in Alzheimer's disease.